Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL versus VANDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL versus VANDAZOLE.
FLAGYL vs VANDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
VANDAZOLE is a nitroimidazole antimicrobial agent that undergoes reduction by bacterial nitroreductases, forming cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
2 g orally as a single dose once daily for 2 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
Approximately 8-10 hours in adults; prolonged to 20-25 hours in hepatic impairment.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Primarily renal (40-70% unchanged), with biliary/fecal elimination accounting for 15-20% as metabolites.
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic